Du är här

2014-05-13

Ablynx: ABLYNX TO PRESENT AT THE 2014 UBS GLOBAL LIFE SCIENCES CONFERENCE

GHENT, Belgium, 13 May 2014
-Ablynx[Euronext Brussels: ABLX]

announces that it will be presenting at the 2014 UBS Global Life Sciences
Conference, which is taking place from 19 till 21 May 2014 at the Sheraton
New York Hotel, New York.

The presentation, followed by a Q&A, will be hosted by Dr Edwin Moses, CEO of
Ablynx,
on Monday 19 May at 09:00 a.m. EST / 03:00 p.m. CET, and will provide an
update on the Company's late-stage proprietary Nanobody®programmes, its
growth and partnering strategy and the outlook for the near term future.

The presentation will be webcast live and can be accessed on the day via
thislinkor via the Ablynx website atwww.ablynx.com. A replay of the webcast
will be available on the Company's website for 30 days following the
presentation. To ensure a timely connection, it is recommended that users
register at least 10 minutes prior to the scheduled webcast.

About Ablynx

Ablynxis a biopharmaceutical company engaged in the discovery and development
ofNanobodies®, a novel class of therapeutic proteins based on single-domain
antibody fragments, for a range of serious human diseases, including
inflammation, haematology, oncology and pulmonary disease. Today, the Company
has approximately30 programmes in the pipelineand seven Nanobodies in
clinical development. Ablynx has on-going research collaborations and
significant partnerships with companies including AbbVie, Boehringer
Ingelheim, Merck&Co, Merck Serono and Novartis. The Company is headquartered
in Ghent, Belgium.

More information can be found onwww.ablynx.com.

For more information, please contact

Ablynx:

Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
+32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com

Follow us on Twitter @AblynxABLX

Ablynx media relations
Consilium Strategic Communications:

Mary-Jane Elliott, Amber Bielecka, Lindsey Neville
t: +44 203 709 5700
e: ablynx@consilium-comms.com

pdf version of the press release
http://hugin.info/137912/R/1785095/611937.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ablynx via Globenewswire

HUG#1785095

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.